You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
14
Nov 24
Publication quarterly financial report (call-date Q3)
01
Aug 24
Publication half-yearly financial report
15
May 24
Publication quarterly financial report (call-date Q1)
26
Apr 24
Annual General Meeting
07
Mar 24
Publication annual financial report
09
Nov 23
03
Aug 23
11
May 23
02
Mar 23
10
Nov 22
04
Aug 22
12
May 22
Mar 22
Nov 21
05
Aug 21
May 21
Mar 21
Nov 20
Publication quarterly statement (call-date Q3)
06
Aug 20
May 20
Publication quarterly statement (call-date Q1)
Mar 20
Annual Press Conference
Nov 19
08
Aug 19
May 19
Apr 19
Mar 19
Nov 18
Aug 18
May 18
Mar 18
Nov 17
Aug 17
18
May 17
Mar 17
4 October 2024
26 July 2024
Merck KGaA: Strong 2nd Quarter, Guidance raised
24 June 2024
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
23 May 2024
21 May 2024
16 May 2024
18 November 2024
Q3 statement / Q3 financial report 2024
8 August 2024
Half-yearly financial report 2024
15 May 2024
Q1 statement / Q1 financial report 2024
13 August 2009
Original-Research: Merck KGaA (von GBC AG):